Does UFP Technologies, Inc. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores UFP Technologies, Inc. (UFPT) 54.5 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 41, returns on capital 57, balance-sheet safety 59, capital discipline 66.

Is UFPT stock trading below its intrinsic value?

Against a deliberately conservative owner-earnings model (9% discount rate, 4% assumed growth, capped at 4%), estimated intrinsic value is $106.98 per share versus a recent price of $242.05 — 126% above value. This is an educational estimate computed from primary SEC filings, not investment advice.

How has UFPT's Moat Score changed over time?

The record logs 3 readings since Jul 17, 2026; the latest reads 54.5 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

UFP Technologies, Inc.

UFPT · Healthcare · $1.9B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power41

Median gross margin 25.4% over 10y, very stable.

Returns on capital57

Median ROIC 11.6%, above the 9% hurdle in 80% of years.

Balance-sheet safety59

Net debt/EBITDA 1.0x, interest coverage 9x.

Capital discipline66

Owner earnings +27.0%/yr, share count growing (dilution).

Margin of safety

Above valueOn sale

126% above value

Owner earnings (normalized): $45.8M
Est. intrinsic value / share: $106.98
Recent price: $242.05
Discount to value: 126% above value

Conservative model: 9% discount rate, 4% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

18 years of fundamentals

The business, in plain English

UFP Technologies, Inc. booked $602.8M of revenue in FY2025 in the Healthcare sector and kept 28.3% of it as gross profit — a moderate-margin business by that measure. After every other cost, 11.3% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $99.2M (FY2009) to $602.8M (FY2025) — about 11.9% a year compounded over 16 years.

It earned 14.2% on invested capital in FY2025, with a median of 13.0% across 17 filed years. The Returns on Capital filter above scores it 57/100.

The balance sheet carried $135.5M of total debt in FY2025 against $68.3M of owner earnings — roughly 2.0 years of owner earnings to retire it all. Balance-Sheet Safety scores it 59/100.

The share count rose 21.7% between FY2010 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 66/100.

Put together: Capital Discipline is the strongest of the four filters (66/100) and Pricing Power the weakest (41/100), which is how UFPT lands at 55/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$602.8M FY2025

Gross marginRevenue kept after cost of goods28.3% FY2025

Return on invested capitalOperating profit on the capital employed14.2% FY2025

Owner earningsCash an owner could take out$68.3M FY2025

Gaps in a line mean that item isn’t in UFPT’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale54.5 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — UFPT has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#100 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#98PTCT PTC Therapeutics, Inc.54.8 out of 100, Shallow moatShallow moat
#99FTV Fortive Corp54.7 out of 100, Shallow moatShallow moat
#101NAGE Niagen Bioscience, Inc.54.5 out of 100, Shallow moatShallow moat
#102INTT InTest Corporation53.7 out of 100, Shallow moatShallow moat

Compare UFPT with its nearest peers →All Healthcare companies on the Index →

Common questions about UFPT

Does UFP Technologies, Inc. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores UFP Technologies, Inc. (UFPT) 54.5 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 41, returns on capital 57, balance-sheet safety 59, capital discipline 66.
Is UFPT stock trading below its intrinsic value?: Against a deliberately conservative owner-earnings model (9% discount rate, 4% assumed growth, capped at 4%), estimated intrinsic value is $106.98 per share versus a recent price of $242.05 — 126% above value. This is an educational estimate computed from primary SEC filings, not investment advice.
How has UFPT's Moat Score changed over time?: The record logs 3 readings since Jul 17, 2026; the latest reads 54.5 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows UFPT’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/UFPT"
  width="340" height="150" style="border:0"
  title="UFPT Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell UFPT. See the disclaimer.